Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure
The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Research Center
Detroit, Michigan, United States
Research Center
Tupelo, Mississippi, United States
Research Center
Cardiff, New South Wales, Australia
Research Center
Melbourne, Victoria, Australia
Start Date
October 1, 2015
Primary Completion Date
October 1, 2016
Last Updated
October 28, 2016
10
ACTUAL participants
Vepoloxamer
DRUG
5% dextrose in water
OTHER
Lead Sponsor
Mast Therapeutics, Inc.
NCT06019169
NCT07325942
NCT05934565
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions